Kalaris Therapeutics (KLRS) Operating Leases (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Operating Leases of $1.1 million for Q1 2026, down 3.45% quarter-over-quarter from $1.1 million in Q4 2025.
Kalaris Therapeutics (KLRS) Operating Leases (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Operating Leases changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, changed N/A from the prior year.
- Operating Leases for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
- The five-year high for Operating Leases was $28.2 million in Q4 2022, with the low at $1.1 million in Q1 2026.
- The 5-year median for Operating Leases is $19.8 million (2022), against an average of $15.6 million.
- The sharpest annual moves came in 2022 and 2024: Operating Leases surged 367.7% in 2022, then slumped 60.9% in 2024.
- Kalaris Therapeutics' Operating Leases stood at $28.2 million in 2022, then sank by 41.01% to $16.6 million in 2023, then tumbled by 45.94% to $9.0 million in 2024, then tumbled by 87.42% to $1.1 million in 2025, then decreased by 3.45% to $1.1 million in 2026.
- Business Quant data shows KLRS's Operating Leases at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Mn |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | 16.05 Mn |
| Dec 31, 2023 | 16.65 Mn |
| Sep 30, 2023 | 19.91 Mn |
| Jun 30, 2023 | 23.02 Mn |
| Mar 31, 2023 | 25.55 Mn |
| Dec 31, 2022 | 28.22 Mn |
| Sep 30, 2022 | 19.75 Mn |
| Jun 30, 2022 | 20.27 Mn |
| Mar 31, 2022 | 20.78 Mn |
| Dec 31, 2021 | 23.48 Mn |
| Sep 30, 2021 | 17.30 Mn |
| Jun 30, 2021 | 4.33 Mn |
| Mar 31, 2021 | 5.41 Mn |
| Dec 31, 2020 | 5.46 Mn |
| Sep 30, 2020 | 6.29 Mn |